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Background:Magnesium sulphate given to women immediately prior to very preterm birth protects the peri-
natal brain, so fewer babies die or develop cerebral palsy. How magnesium sulphate exerts these beneficial
effects remains uncertain. The aim of the MagNUM Study was to assess the effect of exposure to antenatal
magnesium sulphate on MRI measures of brain white matter microstructure at term equivalent age.
Methods: Nested cohort study within the randomised Magnesium sulphate at 30 to <34 weeks’ Gestational
age Neuroprotection Trial (MAGENTA). Mothers at risk of preterm birth at 30 to <34 weeks’ gestation were
randomised to receive either 4 g of magnesium sulphate heptahydrate [8 mmol magnesium ions], or saline
placebo, infused over 30 min when preterm birth was planned or expected within 24 h. Participating babies
underwent diffusion tensor MRI at term equivalent age. The main outcomes were fractional anisotropy
across the white matter tract skeleton compared using Tract-based Spatial Statistics (TBSS), with adjustment
for postmenstrual age at birth and at MRI, and MRI site. Researchers and families were blind to treatment
group allocation during data collection and analyses.
Findings: Of the 109 participating babies the demographics of the 60 babies exposed to magnesium sulphate
were similar to the 49 babies exposed to placebo. In babies whose mothers were allocated to magnesium sul-
phate, fractional anisotropy was higher within the corticospinal tracts and corona radiata, the superior and
inferior longitudinal fasciculi, and the inferior fronto-occipital fasciculi compared to babies whose mothers
were allocated placebo (P < 0.05).
Interpretation: In babies born preterm, antenatal magnesium sulphate exposure promotes development of
white matter microstructure in pathways affecting both motor and cognitive function. This may be one
mechanism for the neuroprotective effect of magnesium sulphate treatment prior to preterm birth.
Funding: Health Research Council of New Zealand.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)ther).
V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Babies born preterm compared with those born at term have a
higher chance of dying in the first few weeks of life. Those who survive
have a greater risk of neurologic impairments, including cerebral palsy,cognitive dysfunction, educational difficulties and psychiatric disorders
in adulthood, with increased educational and societal costs [13].
Antenatal magnesium sulphate is recommended for neuroprotec-
tion of the fetus in women at risk of very preterm birth [4], having
been shown in individual participant data meta-analysis of relevant
randomised trials to reduce the risk of death and cerebral palsy [5].
How magnesium exerts this protective effect, and whether magne-
sium protects parts of the brain that are important for learning and
behaviour as well as those that control movement and posture,
remains uncertain.
Panel: Research in context
Evidence before this study
Antenatal magnesium sulphate is recommended in clinical
practice guidelines worldwide for women at risk of very pre-
term birth for neuroprotection of their fetus. Our recent indi-
vidual participant data meta-analysis, that included five,
relevant, randomised trials with a total of 5493 women and
6131 babies, found antenatal magnesium sulphate given prior
to preterm birth reduces the risk of cerebral palsy and death or
cerebral palsy. What has remained uncertain is how magne-
sium exerts these neuroprotective effects, and whether magne-
sium protects parts of the brain that are important for learning
and behavior as well as those that control movement and
posture.
Added value of this study
MagNUM is a prospective, multicentre, cohort study, recruiting
participants from five, tertiary, maternity hospitals in New Zea-
land and Australia, designed to compare brain white matter
microstructure at term equivalent age between babies whose
mothers were randomised to receive either antenatal magne-
sium sulphate or placebo.
We wished to assess whether magnesium sulphate would
have neuroprotective effects on the white matter tracts that
subserve motor and cognitive function. To our knowledge this
is the first comparative study to explore neuroprotective mech-
anisms for antenatal magnesium sulphate using diffusion ten-
sor magnetic resonance imaging.
Our results show that babies exposed to magnesium sul-
phate compared to babies not exposed had higher fractional
anisotropy (FA) and lower radial diffusivity (RD) in key white
matter tracts at term equivalent age consistent with greater
fibre coherence and maturation, including improved myelina-
tion. Within the corticospinal tracts, reduced FA at term equiva-
lent age in babies born preterm predicts motor delay and
cerebral palsy. We also found higher FA and lower RD within
association fibres that subserve cognitive processes.
Implications of all the available evidence
Our findings show that antenatal magnesium sulphate prior to
preterm birth promotes white matter development in path-
ways important for motor and cognitive function. These data
provide previously lacking evidence as to how magnesium sul-
phate may exert its clinical neuroprotective benefits, including
reducing the risk of cerebral palsy.
2 T. Poppe et al. / EBioMedicine 59 (2020) 102957Dysmaturation of developing white matter is an important neuro-
pathological substrate of adverse neurological outcome after preterm
birth [6]. It arises from upstream insults of hypoxia, ischaemia, and
inflammation, which lead to primary injury or death of key cellular
elements followed by secondary dysmaturation. The cells that are
most susceptible are pre-myelinating oligodendrocytes, but axons
within white matter, and subplate, thalamic and late migrating
GABAergic neuronal populations are also affected. The end result of
injurious and maldevelopmental processes affecting this range of cell
types is a constellation of features, collectively termed the ‘encepha-
lopathy of prematurity’, that are apparent on neonatal MRI as altera-
tions in white and grey matter microstructure, impaired cortical
folding and disturbances to regional brain growth [6].
Diffusion tensor magnetic resonance imaging (DTI) has provided
valuable insights into the effects of maturational and injurious pro-
cesses in the developing brain [7]. This is rooted in the premise thatwater movement is restricted by the presence of axons, neuronal
cell bodies, glial cells and macromolecules, and this allows infer-
ence about brain water content, axonal density, axonal calibre,
myelination, dendritic arborisation and synapse formation. Com-
monly used DTI parameters are fractional anisotropy (FA), which
describes the directional dependence of random water motion,
mean diffusivity (MD) a measure of the magnitude of water
motion, axial diffusivity (AD), the largest eigenvalue of the diffu-
sion tensor in each voxel, potentially indicative of water diffusion
parallel to axons, and radial diffusivity (RD), the average of the two
remaining eigenvalues, potentially indicative of water diffusion
perpendicular to axons. A consistent finding is that FA increases
and MD decreases with increasing maturation of the preterm brain
[8], reflecting decreasing water content and increasing complexity
of white matter. Lower FA and higher MD are seen in the white
matter of preterm infants at term equivalent age compared with
healthy infants born at term [911].
Tract-Based Spatial Statistics (TBSS) enables unbiased group-wise
analysis of FA within the white matter derived from DTI data [9,12].
TBBS has been used to map microstructural alterations in neonatal
white matter tracts associated with preterm birth [13], intrauterine
inflammation [14], maternal opioid use [15], and early life nutrition
[16], and has proven useful for investigating neuroprotective treat-
ments in newborns including erythropoietin for preterm brain injury,
and therapeutic hypothermia and inhaled xenon for hypoxic-ischae-
mic encephalopathy [17,18].
In this paper, we report TBSS results from the Magnesium for Neu-
roprotection: Understanding Mechanisms (MagNUM) Study which
employed DTI to compare brain white matter microstructure at term
equivalent age between babies whose mothers were randomised to
receive antenatal magnesium sulphate and those randomised to
receive placebo. Our hypothesis was that magnesium sulphate would
have neuroprotective effects in the white matter tracts that subserve
motor and cognitive function. Since brain white matter microstruc-
ture is also influenced by gestational age, sex, multiple pregnancy,
breast milk intake and serious neonatal illness such as bronchopul-
monary dysplasia and necrotising enterocolitis, we also explored the
effect of these factors on our findings using subgroup and sensitivity
analyses.
2. Methods
2.1. Study design and participants
The MagNUM Study was nested within the multicentre Magne-
sium Sulphate at 30 to <34 weeks’ Gestational age Neuroprotection
Trial (MAGENTA) comparing magnesium sulphate (magnesium sul-
phate heptahydrate: 8 mmol magnesium ions) with placebo (saline)
in women at risk of imminent (within 24 h) preterm birth at 30 to
<34 weeks’ gestation for the prevention of death or cerebral palsy,
the primary outcome [19] (Australian New Zealand Clinical Trials
Registry ACTRN12611000491965). The central randomisation service
stratified by collaborating centre, gestational age (30 to <32 weeks;
32 to <34 weeks’ gestation) and number of fetuses (1 or 2).
Babies born to mothers enrolled in the MAGENTA Trial at Auck-
land City Hospital, Middlemore Hospital, and Christchurch Women’s
Hospital, New Zealand, and Women’s and Children’s Hospital and
Flinders Medical Centre, Adelaide, Australia, were eligible for enrol-
ment in the MagNUM Study. Exclusion criteria were known congeni-
tal or genetic disorders likely to affect brain structure, baby too
unwell to have an MRI scan safely, or the family lived more than a
one-hour drive from the MRI centre. Written informed consent was
obtained from the caregiver of eligible babies. The MagNUM Study
was approved by the New Zealand Northern B Health and Disability
Ethics Committees LRS/12/06/021/AM02 and by the South Australian
Human Research Ethics Committee HREC/16/WCHN/196.
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MRI was conducted at term equivalent age (38 to 42 weeks’ post
menstrual age) on a 3 Tesla Siemens Skyra system at the Auckland
Centre for Advanced MRI and the South Australia Medical Research
Institute in Adelaide, and a 3 Tesla General Electric HDxt system at
Pacific Radiology in Christchurch, using a 32 channel adult head coil.
Babies were scanned in a neonate MRI beanbag evacuated for stabili-
zation during natural sleep following a feed and swaddling.
To ensure the validity and robustness of inter-site DTI compari-
sons, the MRI protocol was standardised to acquire whole brain diffu-
sion-weighted and high resolution T1 - and T2 - weighted anatomical
MRI data with the same number of baseline and diffusion encoding
gradient directions, b-values, slice locations and voxel dimensions
(Table 1). A detailed written protocol was provided to the radiogra-
phers at all sites.2.3. Outcomes
The primary outcome was regional group differences in FA through-
out the cerebral white matter skeleton measured using TBSS. Secondary
outcomes were group differences in MD (average diffusion along the
three main axes of the diffusion tensor), axial diffusivity (AD, parallel to
the white matter tract) and radial diffusivity (RD, perpendicular to the
main axis of the diffusion tensor). Based on computational modelling
[20] and precedent from the TOBY-Xenon neonatal neuroprotective
hypothermia randomised trial [18] a study of 60 infants in each treat-
ment group was estimated to be able to detect a 10% difference in FA
with 80% power and two-sided 5% significance.2.4. Statistical analysis
Analyses followed a statistical analysis plan prepared prior to any
data analyses. Pre-specified reasons for participants to be excluded
from TBSS analyses were if there was significant brain injury defined
as parenchymal injury or brain abnormality identified on structural
MRI by clinical reviewers and considered likely to confound image
registration; if there was no diffusion MRI, scanner error, or excessive
motion; if more than 10 diffusion weighted MRI volumes had slice
dropout, if registration failed. Application of these exclusions criteria
was done blind to treatment group allocation to reduce the risk of
selection bias in deriving the MagNUM Study per-protocol popula-
tion. Researchers were blind to treatment group allocation until anal-
yses were completed.
DTI data were analysed using the Oxford Centre for Functional Mag-
netic Resonance Imaging of the Brain Software Library, version 5.0.10.
(https://fsl.fmrib.ox.ac.uk/fsl) [21] and DTI-ToolKit (v2.3.1 www.dti-tk.
sourceforge.net) (DTI-TK) [22]. Data were corrected for phase encoding
distortions, eddy-induced distortions and motion using the topup-eddy
algorithm [21], using T2 structural volumes rigidly registered to b0Table 1
Summary table of DTI parameters used in the scanners at the stu
Siemens Skyra (Auckland an
T2 weighted MRI Sampling perfection with ap
using a different flip angle
Repetition time 3200 ms
Echo time 405 ms
Voxels 09 £ 09 £ 1 mm
Field of view 180 mm
Diffusion weighted MRI
Repetition time 7300 ms
Echo time 106 ms
Voxels 2 mm3
Field of view 256 mm
Diffusion weighted directions 64
b-value 750
b0 images 11
Phase-encoding Right to leftmaps and assuming a bandwidth of zero (no phase-encoding) [23]. A
diffusion tensor model was fitted to each voxel and the eigenvalues and
eigenvectors were used to convert the corrected diffusion weighted
images into diffusion tensor volumes (DTI-TK).
Tensor-based image registration (DTI-TK) was used to produce a
population specific diffusion tensor template. From this template the
mean FA volume was derived and thinned by perpendicular non-
maximum suppression to create the mean white matter tract skele-
ton, thresholded at FA > 0.15 to exclude peripheral tracts [9]. All par-
ticipants’ diffusion tensor volumes were registered to the diffusion
tensor template and FA, MD, AD and RD were extracted and projected
onto the white matter tract skeleton.
TBSS [12] was used to compare voxel-wise statistics across the
white matter skeleton between treatment groups, using a general lin-
ear model adjusting for post menstrual age at birth and at MRI, and
scan site. Significance was set as P < 0.05, following family-wise error
rate correction and threshold-free cluster enhancement.
Pre-specified sensitivity analyses included only babies who were
exposed to at least some of the treatment allocated at randomisation
to the MAGENTA Trial (magnesium sulphate or saline placebo);
scanned at the largest MRI site; singletons; born before 34 weeks’
gestation; without bronchopulmonary dysplasia or necrotising
enterocolitis; and exclusively received breast milk at the time of
scanning. Pre-specified subgroup analyses assessed gestation at trial
entry (30 to<32 weeks and 32 to<34 weeks), and boys and girls sep-
arately, and were not adjusted for scan site. For the sensitivity and
subgroup analyses, where smaller sample sizes were expected to
limit power, a pre-specified sequential analysis was undertaken.
Magnesium sulphate and placebo groups were initially compared
using TBSS analysis. If no significant differences were detected, a
region-of-interest analysis was undertaken to determine if the direction
of effect was consistent with the primary analysis. Voxels with signifi-
cant between group differences in the primary analysis were used as
the region of interest. Regions of interest were defined separately for
FA, MD, AD and RD.2.5. Role of the funding sources
The funders of the study had no role in study design, data collec-
tion, analysis, interpretation, or writing of the report. The corre-
sponding author had full access to all the data in the study and had
final responsibility for the decision to submit for publication.3. Results
Of 191 babies eligible for the MagNUM Study, 159 babies were
recruited for MRI at term equivalent age and, after exclusions, DTIdy sites.
d Adelaide) GE HDxT (Christchurch)
plication optimized contrasts
evolution (SPACE)
GE SPACE (“CUBE”)
2500 ms
100 ms
1 £ 1 £ 1 mm
180 mm
7300 ms
97 ms
2 mm3
256 mm
64
750
11
Right to left
4 T. Poppe et al. / EBioMedicine 59 (2020) 102957data from 109 babies (60 in the magnesium sulphate group ande-
tus 49 in the placebo group) were included (Fig. 1). The per-pro-
tocol MagNUM Study population of mothers and babies were
similar in the magnesium sulphate and placebo groups in their
demographics at entry into the MAGENTA Trial and after birth
(table 2).
Babies whose mothers were randomised to antenatal magne-
sium sulphate compared with babies whose mothers were rando-
mised to placebo had significantly higher FA including in the
superior portions of the corticospinal tracts and the inferior
fronto-occipital fasciculi bilaterally, and in the right corona radi-
ata, the right superior longitudinal fasciculus, the right precentral
and postcentral gyri, the right posterior limb of the internal cap-
sule, and the left inferior longitudinal fasciculus (Fig. 2).
The magnesium sulphate group had reduced RD in the superior
corona radiata (magnesium sulphate group mean § standard devia-
tion; 1.18 § 0.08, placebo group 1.23 § 0.09) and the right precentral
gyrus. There were no significant differences in MD or AD between
the treatment groups in any region and there were no regions where
FA was higher or RD lower in the placebo than in the magnesium sul-
phate group (Fig. 2).Magnesium sulphate
n= 100 (52%)
MRI included in 
TBSS
n = 60 (70%)
Not assessed n= 14 (14%)
Not approached n= 1 (1%)
Declined n= 12 (12%)
Lives remotely n= 1 (1%)
Assessed in 
MagNUM at term 
equivalent age
n= 86 (86%)
No MRI for analysis n= 26 (30%)
Severe brain injury n= 1 (1%)
No diffusion MRI n= 3 (3%)
Scanner error n= 5 (6%)
Excessive motion n= 16 (19%)
Failed registration n= 1 (1%)
MAGENTA 
eligible fo
n= 19
Fig. 1. MagNUM Study recruitment and inclusion in3.1. Sensitivity analyses
When only babies whose mother received at least some of the
allocated treatment were included (n = 107; 59 magnesium sul-
phate, 48 placebo) the findings were similar to the primary analysis
(Fig. 3a).
When including only babies who were scanned at the largest
MRI site (n = 66; 33 magnesium sulphate, 33 placebo) there were no
significant differences between groups on whole skeleton TBSS
analysis, but on region-of-interest analysis, the magnesium sulphate
group had marginally higher FA (mean § standard deviation; 0.25§
0.02) than the placebo group (0.23§0.02, P = 0.025) but RD did not
differ (magnesium sulphate group 1.21§0.08 £ 103 mm2 s  1, pla-
cebo group 1.24§0.07 £ 103 mm2 s1, (P = 0.07)). When including
only babies born before 34 weeks’ gestation (n = 106; 60 magnesium
sulphate, 46 placebo) the findings were similar to the primary anal-
ysis (Fig. 3b).
When only singletons were included (n = 79; 41 magnesium sul-
phate, 38 placebo), there were no significant differences between
groups on whole skeleton TBSS analysis. On region-of-interest analy-
sis, the magnesium sulphate group had slightly higher FA (0.25§0.02)Placebo Group
n = 91 (48%)
Not assessed n= 18 (20%)
Not approached n= 5 (5%)
Declined n= 9 (10%)
Lives remotely n= 4 (4%)
MRI included in 
TBSS
n = 49 (67%)
Assessed in 
MagNUM at term 
equivalent age
n= 73 (80%)
No MRI for analysis n= 24 (33%)
Severe brain injury n= 2 (3%)
No diffusion MRI n= 2 (3%)
Scanner error n= 5 (7%)
Excessive motion n= 15 (21%)
Failed registration n= 0 (0%)
babies 
r MRI
1
Tract-Based Spatial Statistics (TBSS) analysis.
Table 2
Characteristics of mothers and babies in the MagNUM Study.
Characteristics Magnesium sulphate Placebo p value
Mothers n = 52 n = 45
Age (years) 321 (53) 309 (71) 036
Nulliparous 28 (538) 27 (600) 054
Ethnicity 043
. Caucasian 24 (462) 17 (378)
. Asian 12 (231) 7 (156)
. Aboriginal or Torres Strait
Islander
1 (19) 0 (00)
. Polynesian 3 (58) 2 (44)
. Maori 5 (96) 7 (156)
. Other 7 (135) 12 (267)
BMI (kg/m2) 269 (72) 264 (52) 070
Gestation at trial entry (weeks) 319 (10) 319 (12) 070
Main reason at risk of preterm
birth:
. Antepartum haemorrhage 6 (115) 5 (111) 095
. Preterm prelabour rupture of
membranes
16 (308) 16 (356) 062
. Preterm labour 24 (462) 19 (422) 070
. Pre-eclampsia 9 (173) 8 (178) 095
. Fetal compromise 11 (212) 5 (111) 018
. Other 11 (212) 10 (222) 090
Received treatment allocated 51 (981) 44 (978) 092
Babies n = 60 n = 49
Gestation at birth (weeks) 319 (09) 322 (16) 028
Twins 053
. Singleton 41 (683) 38 (776)
. Twin 1 10 (167) 5 (102)
. Twin 2 9 (150) 6 (122)
MRI site 015
. Auckland 33 (550) 33 (673)
. Christchurch 16 (267) 13 (265)
. Adelaide 11 (183) 3 (61)
Post-menstrual age at MRI
(weeks)
401 (15) 402 (13) 075
Birth weight (g) 1663 (362) 1821 (536) 008
Birth weight (z score) 004 (104) 025 (109) 016
Bronchopulmonary dysplasia 6 (100) 2 (41) 024
Necrotising enterocolitis 0 0
Exclusive breast milk feeding at
time of MRI
39 (650) 36 (735) 041
Sex (Female) 27 (450) 23 (469) 084
Data are mean (standard deviation) or n (%). Bronchopulmonary dysplasia was
defined as oxygen requirement at 36 week’s post-menstrual age. Z scores were calcu-
lated using WHO standards.38.
Fig. 2. Tract-based spatial statistics comparing the brain white matter skeletons at
term equivalent age of babies exposed in utero to magnesium sulphate or placebo.
Footnote: A group-specific template underlies each axial (top four rows) coronal
(middle four rows) and sagittal (bottom four rows) slices, with the white matter tract
skeleton shown in green. Regions where the magnesium sulphate group (n = 60) had a
significantly higher diffusion metric than the placebo group (n = 49) are shown in red-
yellow (family-wise error corrected, P < 005), while regions where the magnesium
sulphate group had significantly lower measures than the placebo group are in blue.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
T. Poppe et al. / EBioMedicine 59 (2020) 102957 5than the placebo group (0.24§0.03, (P = 0.034)) but there was no sig-
nificant difference in RD (1.18§0.09 £ 103 mm2 s1 vs 1.21§
0.09£ 103 mm2 s1, (P = 0.10)).
When only babies without bronchopulmonary dysplasia were
included (n = 101; 54 magnesium sulphate, 47 placebo), the find-
ings were similar to the primary analysis but there were no signifi-
cant differences in the superior longitudinal fasciculus or the
inferior fronto-occipital fasciculus. However, the magnesium sul-
phate group had lower MD in the precentral gyrus, and more
extensive clusters with significantly lower RD in both the left and
right corona radiata (Fig. 3c). There were no differences between
groups in AD.
When only babies who were exclusively receiving breast milk at
the time of MRI were included (n = 75; 39 magnesium sulphate, 36
placebo), FA results were similar to the primary analysis, but with
more differences between groups in the left hemisphere. The magne-
sium sulphate group had higher FA in the left superior longitudinal
fasciculus, the left and right optic radiations, the left and right corti-
cospinal tracts (including the left posterior limb of the internal
capsule), and precentral gyri (Fig. 3d). There were no significant
differences between groups in MD, AD or RD.
Fig. 3. Sensitivity and subgroup tract-based spatial statistics comparing the white matter skeletons of babies at term equivalent age of babies exposed in utero to magnesium sul-
phate or placebo
Footnote: A group-specific template underlies each axial (right) coronal (middle) and sagittal (left) slices, with significant primary analysis differences between the magnesium
and placebo groups indicated in green. Regions where babies who received magnesium sulphate had a significantly (family-wise error corrected, (P< 005)) higher FA (red-yellow),
lower RD (blue) or lower MD (pink) than babies who received placebo are layered over the template.
a: Babies whose mother received at least some of their allocated treatment;
b: Babies born <34 weeks’ gestation;
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In the subgroup of babies randomised at 30 to <32 weeks’ gesta-
tion (n = 56; 30 magnesium sulphate, 26 placebo) there were no sig-
nificant differences between groups in any regions of the white
matter skeleton. On region-of-interest analysis, there were also no
differences between groups in FA or RD. In the subgroup of babies
randomised at 32 to <34 weeks’ gestation (n = 53; 30 magnesium
sulphate, 23 placebo), the magnesium sulphate group had higher FA
in a cluster of the left inferior longitudinal fasciculus (Fig. 3e). There
were no significant differences between groups in MD, AD or RD.
When babies of each sex were analysed separately (50 girls; 27
magnesium sulphate, 23 placebo, and 59 boys; 33 magnesium sul-
phate, 26 placebo) there were no significant differences between
treatment groups on TBSS analysis. On region-of-interest analysis,
boys in the magnesium sulphate group had higher FA than those in
the placebo group (0.25§0.02 vs 0.24§0.03, (P = 0.01)) and lower RD
(1.19§0.08 vs 1.24§0.09 £ 103 mm2 s1, (P = 0.03)). For girls, there
were no differences in the region-of-interest analyses for FA or for
RD.4. Discussion
Antenatal magnesium sulphate administered to mothers at risk of
imminent preterm birth from 30 to <34 weeks’ gestation protected
white matter development in their babies. At term equivalent age,
key white matter tracts of babies exposed to antenatal magnesium
sulphate compared with those babies not exposed had higher FA and
lower RD, indicating greater fibre coherence and maturation along
the axis of greatest water molecule diffusion. Furthermore, the reduc-
tion in RD is consistent with a protective effect resulting in improved
myelination. Effects in corticospinal tracts are of importance because
reduced FA of the corticospinal tract at term equivalent age in babies
born preterm independently predicts motor delay and cerebral palsy
[24]. The effects of magnesium sulphate reached the white matter
underlying the cortex in the pre- and post-central gyri which are the
primary sensory and motor cortices. Our findings are consistent with
the neuroprotective benefits, including lower rates of cerebral palsy,
observed after exposure to antenatal magnesium sulphate before 30
weeks’ gestation [25].
The effects of antenatal magnesium sulphate on FA and RD were not
confined to motor pathways and extended to the superior longitudinal
fasciculus, inferior longitudinal fasciculus and the inferior fronto-occipi-
tal fasciculus. These association fibres subserve cognitive processes
including regulation of motor behaviour, visually guided behaviors, lan-
guage, and working memory, and all are implicated in the cerebral phe-
notype of preterm brain injury [23,26,27]. Furthermore, alterations in
DTI parameters have been associated with cognitive deficits in children
and adults born preterm [28,29], Our findings therefore suggest that
children in the magnesium sulphate group may have improved cogni-
tive as well as motor outcomes. Participants in the MAGENTA Tria [19],
are currently being assessed at two years of age for the primary out-
come, which will enable further assessment of the neuroprotective
effect of magnesium sulphate and outcome across a broad range of
developmental domains.
As this was a nested study within a multicentre randomised trial,
we used three different MRI facilities to maximise recruitment. To
ameliorate the possible confounding effects of scanner variation,
image acquisition sequences were matched as closely as possible,
scan site was included as a covariate in primary analysis, and wec: Babies who did not have bronchopulmonary dysplasia or necrotising enterocolitis;
d: Babies who were exclusively fed breast milk at the time of MRI;
e: Babies who were 32 to <34 weeks’ gestation at trial entry.(For interpretation of the re
article.)carried out a sensitivity analysis using data only from the largest site
(60% of all MRI scans). There were no significant differences between
magnesium sulfate and placebo groups on TBSS analysis, and in the
region-of-interest analysis the direction of effect was maintained.
These results were consistent with the primary analysis.
There were several notable findings from the sensitivity analyses.
When only singletons were included (73% of the cohort) there were
no differences between groups on TBBS analysis, and the direction of
effect was maintained on region-of-interest analysis. This is consis-
tent with previous findings which indicate that the clinical effects of
antenatal magnesium sulphate for neuroprotection are similar in sin-
gleton and multiple pregnancies [25].
Breastmilk intake can affect early brain development and later
neurodevelopment after preterm birth, and was therefore a potential
confounder. In very preterm babies, the proportion of early enteral
intake from breastmilk is associated with neonatal white matter con-
nectivity [16,30]. In the subgroup of babies who were exclusively
receiving breastmilk at the time of scanning (74% of the cohort), over-
all findings were similar to those of the primary analysis, although
higher FA was seen in the optic radiations, associated with visual
function, in the magnesium sulphate exposed group.
In sensitivity analyses, we also investigated a group without bron-
chopulmonary dysplasia because of its consistent association with
atypical brain development [9], and found that the beneficial effects
of antenatal magnesium sulphate were apparent in babies without
this comorbidity of preterm birth.
Magnesium sulphate is recommended for fetal neuroprotection in
women at risk of preterm birth although the optimal gestational age
for its use remains uncertain [4,19],[3134]. We found that in babies
randomised at 30 to<32 weeks (51% of the cohort) there were no dif-
ferences between magnesium exposed and placebo groups in any
white matter region, whereas in the babies randomised at 32 <34
weeks (49% of the cohort) there was higher FA in the magnesium
exposed group, although this was restricted to the left inferior longi-
tudinal fasciculus. This finding was unexpected and most likely
explained by a type 2 error due to small subgroups.
Male sex is associated with diffuse white matter injury after pre-
term birth [35]. In extremely preterm babies who underwent MRI at
term equivalent age, boys were reported to have delayed myelination
[36], and lower FA in the splenium of the corpus callosum [37] com-
pared with girls. Although we found no differences in whole skeleton
analysis between the magnesium sulphate and placebo groups in
girls or boys separately, we did observe a modest increase in FA and
lower RD in region-of-interest analysis, which was significant only
for boys. This raises the possibility that boys receive a greater neuro-
protective benefit from magnesium sulphate exposure than girls, and
this warrants further investigation.
Amajor strength of theMagNUM Study is that it was nestedwithin a
randomised controlled trial, so the changes observed after magnesium
sulphate exposure are likely to be causal. Follow-up of the trial partici-
pants will allow assessment of the relationships between the MRI
changes at term equivalent age and later developmental outcomes. A
possible weakness was the sample size, which reduced power to detect
small effects in subgroups of interest including those for gestational age.
However, in all subgroups the direction of the differences in FA and RD
were consistent with those of the primary analysis.
In babies born preterm, antenatal magnesium sulphate exposure
promotes development of white matter microstructure in pathways
affecting both motor and cognitive functions. This may be one mech-
anism for the neuroprotective effect of magnesium sulphate treat-
ment prior to preterm birth.ferences to colour in this figure legend, the reader is referred to the web version of this
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